Abstract
Human papillomavirus (HPV) types 16 and 18 are the main targets in the field of prophylactic vaccines for preventing cervical cancer. L1 protein, the major capsid protein of HPV, selfassembles into virus-like particles (VLP), which are the major component of prophylactic vaccines. To obtain highly purified L1 protein, contaminants must be removed by several chromatography steps. However, this requires a great deal of time and labor, and results in loss of large amounts of the target protein. Therefore, we have sought to develop an efficient method for removing contaminants prior to chromatography during the purification of HPV18 L1 protein from Saccharomyces cerevisiae. For this purpose the contaminating proteins were removed by an ammonium sulfate precipitation step and further removed by a removal of precipitated contaminants step. Purification of the L1 protein by chromatography was significantly improved by the removal of precipitated contaminants step. In the present work we developed two one-step chromatography methods (heparin and cation-exchange chromatography), and HPV18 L1 proteins purified by both methods self-assembled into VLP. The two chromatographic purification methods are simpler and more convenient than previous methods and are widely applicable to work with VLPs.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Aires, K. A., Cianciarullo, A. M., Carneiro, S. M., Villa, L. L., Boccardo, E., Perez-Martinez, G., Perez-Arellano, I., Oliveira, M. L., and Ho, P. L., Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl. Environ. Microbiol., 72, 745–752 (2006).
Bishop, B., Dasgupta, J., and Chen, X. S., Structure-based engineering of papillomavirus major capsid l1: controlling particle assembly. Virol. J., 4, 3 (2007).
Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., and Shah, K. V., Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst., 87, 796–802 (1995).
Buck, C. B., Thompson, C. D., Pang, Y. Y., Lowy, D. R., and Schiller, J. T., Maturation of papillomavirus capsids. J. Virol., 79, 2839–2846 (2005).
Cook, J. C., Joyce, J. G., George, H. A., Schultz, L. D., Hurni, W. M., Jansen, K. U., Hepler, R. W., Ip, C., Lowe, R. S., Keller, P. M., and Lehman, E. D., Purification of virus-like particles of recombinant human papillomavirus type 11 major capsid protein L1 from Saccharomyces cerevisiae. Protein Expr. Purif., 17, 477–484 (1999).
de Witte, L., Zoughlami, Y., Aengeneyndt, B., David, G., van Kooyk, Y., Gissmann, L., and Geijtenbeek, T. B., Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation. Immunobiology, 212, 679–691 (2007).
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W., Ferris, D. G., Steben, M., Bryan, J., Taddeo, F. J., Railkar, R., Esser, M. T., Sings, H. L., Nelson, M., Boslego, J., Sattler, C., Barr, E., and Koutsky, L. A., Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med., 356, 1928–1943 (2007).
Giroglou, T., Florin, L., Schafer, F., Streeck, R. E. and Sapp, M., Human papillomavirus infection requires cell surface heparan sulfate. J. Virol., 75, 1565–1570 (2001).
Hofmann, K. J., Cook, J. C., Joyce, J. G., Brown, D. R., Schultz, L. D., George, H. A., Rosolowsky, M., Fife, K. H. and Jansen, K. U., Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology, 209, 506–518 (1995).
Jeong, H. S., Shin, J. H., Choi, J. Y., Kim, Y. L., Bae, J. J., Kim, B. G., Ryu, S. R., Kim, S. N., Min, H. K., Kim, H. J., and Park, S. N., Evaluation of viral clearance in the production of HPV-16 L1 virus-like particles purified from insect cell cultures. Biologicals, 34, 273–279 (2006).
Jeong, N. H., Lee, N. W., Woo, M. K., and Kim, H. J., Serologic response to human papillomavirus type 16 virus-like particles in Korean women with cervical precancerous and cancerous lesions. Arch. Pharm. Res., 32, 383–389 (2009).
Jeong, N. H., Woo, M. K., Lee, N. W., Hur, S. J., Choi, K. S., and Kim, H. J., Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer. Arch. Pharm. Res., 32, 1013–1018 (2009).
Joyce, J. G., Tung, J. S., Przysiecki, C. T., Cook, J. C., Lehman, E. D., Sands, J. A., Jansen, K. U., and Keller, P. M., The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem., 274, 5810–5822 (1999).
Kim, S. N., Jeong, H. S., Park, S. N., and Kim, H. J., Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae. J. Virol. Methods, 139, 24–30 (2007).
Kirnbauer, R., Papillomavirus-like particles for serology and vaccine development. Intervirology, 39, 54–61 (1996).
Knappe, M., Bodevin, S., Selinka, H. C., Spillmann, D., Streeck, R. E., Chen, X. S., Lindahl, U., and Sapp, M., Surface-exposed amino acid residues of HPV16 L1 protein mediating interaction with cell surface heparan sulfate. J. Biol. Chem., 282, 27913–27922 (2007).
Lowe, R. S., Brown, D. R., Bryan, J. T., Cook, J. C., George, H. A., Hofmann, K. J., Hurni, W. M., Joyce, J. G., Lehman, E. D., Markus, H. Z., Neeper, M. P., Schultz, L. D., Shaw, A. R., and Jansen, K. U., Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J. Infect. Dis., 176, 1141–1145 (1997).
Moscicki, A. B., HPV Vaccines: today and in the Future. J. Adolesc. Health, 43, S26–40 (2008).
Neeper, M. P., Hofmann, K. J., and Jansen, K. U., Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae. Gene, 180, 1–6 (1996).
Park, M. A., Kim, H. J., and Kim, H. -J., Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr. Purif., 59, 175–181 (2008).
Rommel, O., Dillner, J., Fligge, C., Bergsdorf, C., Wang, X., Selinka, H. C. and Sapp, M., Heparan sulfate proteoglycans interact exclusively with conformationally intact HPV L1 assemblies: basis for a virus-like particle ELISA. J. Med. Virol., 75, 114–121 (2005).
Schadlich, L., Senger, T., Kirschning, C. J., Muller, M., and Gissmann, L., Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Vaccine, 27, 1511–1522 (2009).
Wang, X., Sapp, M., Christensen, N. D., and Dillner, J., Heparin-based ELISA reduces background reactivity in virus-like particle-based papillomavirus serology. J. Gen. Virol., 86, 65–73 (2005).
Woo, M. K., An, J. M., Kim, J. D., Park, S. N., and Kim, H. J., Expression and purification of human papillomavirus 18 L1 virus-like particle from Saccharomyces cerevisiae. Arch. Pharm. Res., 31, 205–209 (2008).
Zhou, J., Sun, X. Y., Stenzel, D. J., and Frazer, I. H., Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology, 185, 251–257 (1991).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, H.J., Lim, S.J., Kim, J.Y. et al. A method for removing contaminating protein during purification of human papillomavirus type 18 L1 protein from Saccharomyces cerevisiae . Arch. Pharm. Res. 32, 1759–1766 (2009). https://doi.org/10.1007/s12272-009-2214-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-009-2214-x